Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AGER | Q15109 | 5/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927823 | 1.00 | APAF1 (0.60) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL1026002 | 0.83 | APAF1 (0.67) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL19432570 | 0.81 | APAF1 (0.65) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL14408911 | 0.80 | APAF1 (0.63) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL6176569 | 0.80 | APAF1 (0.68) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL6175278 | 0.80 | APAF1 (0.68) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL13545635 | 0.79 | APAF1 (0.61) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL11200794 | 0.77 | APAF1 (0.60) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL6791275 | 0.76 | GGPS1 (0.64) | APAF1TDP1AGERGGPS1FDPS | |
| SCHEMBL31748263 | 0.76 | TDP1 (0.63) | APAF1TDP1AGERGGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | APAF1 4266/4885TDP1 2035/4885AGER 4242/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | APAF1 4266/4885TDP1 2035/4885AGER 4242/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | APAF1 4266/4885TDP1 2035/4885AGER 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.